Replimune Group, Inc. held its annual meeting on September 3, 2025, where stockholders voted to elect directors, ratify the accounting firm, and approve executive compensation, but rejected an amendment to the incentive plan. Additionally, a meeting with the FDA was scheduled and announced on September 2, 2025.